Shaanxi Meibang Pharmaceutical Group Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 694.02 million compared to CNY 905.41 million a year ago. Revenue was CNY 699.03 million compared to CNY 906.05 million a year ago.

Net income was CNY 57.56 million compared to CNY 145.09 million a year ago. Basic earnings per share from continuing operations was CNY 0.43 compared to CNY 1.07 a year ago. Diluted earnings per share from continuing operations was CNY 0.43 compared to CNY 1.07 a year ago.